Stockscreener 앱 받기
76.26
0.00%
0.00
Bridgebio Pharma Inc 주식(BBIO)의 최신 뉴스
BridgeBio prices $550 million convertible notes at 0.75% interest rate By Investing.com - Investing.com Nigeria
Latham & Watkins Advises on BridgeBio Pharma’s US$550 Million Convertible Senior Notes Offering - Latham & Watkins LLP
BridgeBio Pharma (BBIO) stock edges up after $550 million convertible notes pricing — what investors watch next - TechStock²
Lobbying Update: $60,000 of BRIDGEBIO PHARMA lobbying was just disclosed - Quiver Quantitative
BridgeBio Pharma Prices $550M Convertible Notes Offering with $538.4M Net Proceeds Expected - Intellectia AI
BridgeBio Pharma prices $550M convertible bond offering - MSN
BridgeBio Pharma Prices $550 Million Convertible Notes Offering - Intellectia AI
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
BridgeBio Pharma prices $550 million convertible notes offering By Investing.com - Investing.com Canada
BridgeBio Prices Offering of $550 Million Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027 - The Manila Times
BridgeBio Pharma Prices $550 Mln Of 0.75% Convertible Senior Notes Due 2033 - Nasdaq
BridgeBio Pharma, Inc. Announces Pricing of $550 Million Convertible Senior Notes to Enhance Capital Structure and Extend Debt Maturity - Quiver Quantitative
BridgeBio Prices Offering of $550 Million Convertible - GlobeNewswire
BridgeBio Pharma (NASDAQ:BBIO) Shares Gap DownHere's What Happened - MarketBeat
BridgeBio’s US$550 Million Notes Offering and ATTR-CM Push Could Be A Game Changer For BBIO - Yahoo Finance
Assessing BridgeBio Pharma (BBIO) Valuation After Attruby Uptake And Pipeline Progress - Yahoo Finance
BridgeBio plans $550 million convertible notes offering to refinance debt By Investing.com - Investing.com Nigeria
BridgeBio plans $550M convertible notes offering due 2033 - MSN
BridgeBio Pharma, Inc. Announces Private Offering of $550 Million Convertible Senior Notes to Strengthen Balance Sheet and Extend Debt Maturity - Quiver Quantitative
BridgeBio Continues Long Term Debt Management Strategy and Announces Proposed Offering of Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027 - The Manila Times
BridgeBio continues long term debt management strategy and announces proposed offering of convertible senior notes - marketscreener.com
Ideas Watch: What is the PEG ratio of BridgeBio Pharma IncPortfolio Risk Report & Weekly Return Optimization Plans - baoquankhu1.vn
BridgeBio Pharma (BBIO) Gets a Buy from Raymond James - The Globe and Mail
BridgeBio Pharma stock hits all-time high at 78.69 USD By Investing.com - Investing.com Nigeria
Aug Reactions: Is BridgeBio Pharma Inc stock a value trapJuly 2025 Catalysts & Long-Term Growth Plans - baoquankhu1.vn
Will BridgeBio Pharma Inc stock deliver strong dividend growth2025 Sector Review & Breakout Confirmation Alerts - moha.gov.vn
Evercore ISI Sticks to Its Buy Rating for BridgeBio Pharma (BBIO) - The Globe and Mail
BridgeBio Pharma (NASDAQ:BBIO) Hits New 12-Month HighShould You Buy? - MarketBeat
BridgeBio Pharma stock hits all-time high at 78.69 USD - Investing.com India
Nisa Investment Advisors LLC Grows Stock Holdings in BridgeBio Pharma, Inc. $BBIO - MarketBeat
BridgeBio reports $362.4 million in 2025 Attruby revenue By Investing.com - Investing.com Nigeria
BridgeBio Pharma Highlights Attruby Surge, Preannounces $146M Q4 Revenue at JPM Healthcare Conference - Yahoo Finance
BridgeBio Pharma (NASDAQ:BBIO) CEO Neil Kumar Sells 40,000 Shares - MarketBeat
BridgeBio Pharma CEO Kumar sells $6m in BBIO stock By Investing.com - Investing.com Nigeria
BridgeBio Pharma CEO Kumar sells $6m in BBIO stock - Investing.com
BridgeBio Showcases Attruby Growth and Pipeline Progress - TipRanks
BridgeBio stock maintains Buy rating at TD Cowen on strong Attruby sales - Investing.com Canada
BridgeBio Pharma reports Attruby product revenue $146 mln in Q4 - marketscreener.com
BridgeBio Pharma Reports Attruby Product Revenue $146 Mln In Q4 - TradingView — Track All Markets
BridgeBio reports $362.4 million in 2025 Attruby revenue - Investing.com
BridgeBio (BBIO) Highlights Strategic Advancements at Healthcare Conference - GuruFocus
BridgeBio Announces Commercial Progress, Program Updates, and 2026 Milestones at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
BridgeBio Announces Commercial Progress, Program Updates, and 2026 Milestones at the 44th ... - Bluefield Daily Telegraph
New genetic treatments move closer for heart and rare childhood diseases - Stock Titan
Tema Etfs LLC Sells 27,026 Shares of BridgeBio Pharma, Inc. $BBIO - MarketBeat
Sectors Review: Is BridgeBio Pharma Inc in a bullish channelM&A Rumor & Fast Gaining Stock Reports - baoquankhu1.vn
Aug Wrap: What makes BridgeBio Pharma Inc stock attractive to growth fundsQuarterly Market Summary & Risk Managed Investment Signals - Bộ Nội Vụ
Will BridgeBio Pharma Inc. stock benefit from commodity prices2025 Dividend Review & Daily Profit Maximizing Tips - ulpravda.ru
What hedge fund activity signals for BridgeBio Pharma Inc. stockMarket Sentiment Report & Weekly Chart Analysis and Guides - Улправда
BridgeBio’s receives EU approval for its Transthyretin Amyloidosis treatment - MSN
Discipline and Rules-Based Execution in BBIO Response - Stock Traders Daily
BridgeBio Pharma, Inc. (BBIO) Discusses Achondroplasia Pathophysiology, Unmet Needs, and PROPEL 3 Infigratinib Phase 3 StudySlideshow (NASDAQ:BBIO) 2026-01-09 - Seeking Alpha
BridgeBio Pharma Investor Update: PROPEL 3 “Last Visit” Set as Infigratinib Phase 3 Readout Nears - Yahoo Finance
BBIO: Infigratinib shows strong efficacy and safety in achondroplasia, with high market adoption potential - TradingView — Track All Markets
Can BridgeBio Pharma Inc. stock hit record highs againJuly 2025 Big Picture & Daily Technical Stock Forecast Reports - Улправда
What makes BridgeBio Pharma Inc. stock attractive to growth fundsQuarterly Earnings Summary & Verified Momentum Watchlists - ulpravda.ru
BridgeBio stock soars after breakthrough Phase 3 data for muscular dystrophy treatment - MSN
Why BridgeBio Pharma Inc. stock could rally in 2025Quarterly Market Summary & High Yield Stock Recommendations - Улправда
4.73%
0.92%
자본화:
|
볼륨(24시간):